Question explored with the scientific record
Why is paxlovid not available in the UK to 65 to 75 years?
The short version: the evidence retrieved does not answer why 65–75 year olds in the UK are excluded from Paxlovid, and that gap matters.
The two studies that touch Paxlovid describe the EPIC-HR trial in high-risk adults, not UK prescribing rules [2, 3]. That trial showed fewer hospitalizations with early treatment: 0.8% versus 7% when started within three days of symptoms, and zero deaths versus seven in the placebo arm [3]. But the trial was run by the manufacturer, and the evidence here contains no UK eligibility criteria, no commissioning documents, and no comparison across age bands [2, 3]. Your hypothesis about regulatory labeling and risk stratification is plausible, but the retrieved evidence neither confirms nor refutes it.
The third record is about HIV drug resistance in Uganda [1]. It has nothing to do with Paxlovid or UK policy. I will not stretch it to fill the gap.
| Trial arm (within 3 days) | Hospitalized by day 28 | Deaths by day 28 |
|---|---|---|
| Paxlovid | 0.8% (3/389) | 0 |
| Placebo | 7% (27/385) | 7 |
My call: the evidence retrieved does not address the UK's age-based restriction. Confidence: not clear.
Sources examined 3
-
Lack of effectiveness of adherence counselling in reversing virological failure among patients on long‐term antiretroviral therapy in rural Uganda
Enhanced adherence counselling did not reverse virological failure in long-term ART patients with VL ≥1000 copies/mL at enrolment; only 9 of 102 achieved VL <1000 copies/mL after 3 months.
DOI: 10.1111/hiv.12790 -
Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
Rapid review finds Paxlovid reduces hospitalisation and mortality in high-risk adults with mild-to-moderate COVID-19 and shows a favorable short-term safety profile, but evidence is limited and data on drug interactions remain uncertain.
DOI: 10.18502/htaa.v6i1.11131 -
Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination
Overview of Paxlovid (nirmatrelvir plus ritonavir) as a potent SARS-CoV-2 3CLpro protease inhibitor, detailing its mechanism, early clinical efficacy with rapid administration, dosing, and regulatory status.
DOI: 10.37201/req/002.2022